Evidence map›Paper›PMID 39856623›Full record

ArticleBMC pediatrics2025

The role of cyclooxygenase-2 (COX-2) and inflammatory markers in the progress of Alport syndrome in Egyptian children.

Moushira Zaki, Hisham A Orban, Mohamed A Shahba, Rehab S I Moustafa, Ahmed Adel, Fatina I Fadel, Abeer Selim, Hala T El-Bassyouni, Eman R Youness

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Moushira ZakiBiological Anthropology Department, Medical Research and Clinical Studies Institute, National Research Centre, Cairo, Egypt.
Hisham A OrbanMedical Biochemistry Department, Medical Research and Clinical Studies Institute, National Research Centre, Cairo, Egypt.
Mohamed A ShahbaMedical Biochemistry Department, Medical Research and Clinical Studies Institute, National Research Centre, Cairo, Egypt.
Rehab S I MoustafaChild Health Department, Medical Research and Clinical Studies Institute, National Research Centre, Cairo, Egypt.
Ahmed AdelChild Health Department, Medical Research and Clinical Studies Institute, National Research Centre, Cairo, Egypt.
Fatina I FadelDepartment of Pediatrics, Pediatric Nephrology Unit. Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, Egypt.
Abeer SelimDepartment of Pediatrics, Medical Research and Clinical Studies Institute, National Research Centre, Cairo, Egypt.
Hala T El-BassyouniClinical Genetics Department, Human Genetics and Genome Research Institute, National Research Centre, Cairo, Egypt.
Eman R YounessMedical Biochemistry Department, Medical Research and Clinical Studies Institute, National Research Centre, Cairo, Egypt. hoctober2000@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic inflammation and its control are crucial to the responses of glomerular and renal tubular cells. This contributes to the pathogenic mechanisms and advancement of the disease in Alport syndrome. The study aimed to elucidate the role of cyclooxygenase-2, Interleukin 4, Plasminogen activating inhibitor 1, and Prostaglandin E2 in the development and course of Alport syndrome.

methodsIn our study inflammatory markers were evaluated in 26 Alport syndrome patients, 15 males and 11 females and 24 controls.

resultsTheir age ranged from 4 to 16 years (mean ± SD was 8.50 ± 2.877) and 24 were normal controls matching age and sex. The serum levels of cyclooxygenase-2, Prostaglandin E2, Interleukin 4, and Plasminogen activating inhibitor 1 were evaluated in all patients. The serum level of cyclooxygenase-2, Prostaglandin E2, Interleukin 4, and Plasminogen activating inhibitor 1 were all increased significantly in the Alport syndrome patients compared to control (588.68 ± 73.08, 42.57 ± 4.18, 42.32 ± 3.49, and 846.47 ± 45.433, respectively versus controls (369.12 ± 50.28, 25.52 ± 4.98, 28.89 ± 3.19, and 312.79 ± 40.53 respectively).

conclusionThe role of inflammatory markers cyclooxygenase-2, Prostaglandin E2, Interleukin 4, and Plasminogen activating inhibitor 1 in Alport syndrome that are causally connected and have a role in the development and course of Alport disease was delineated. This may highlight and speculate an innovative strategy for targeting the creation of safe and efficient anti-inflammatory treatments to inhibit disease progression in Alport syndrome.

Indexed as

Cyclooxygenase 2DinoprostoneInterleukin-4Nephritis, HereditaryPlasminogen Activator Inhibitor 1AdolescentBiomarkersCase-Control StudiesChildChild, PreschoolDisease ProgressionEgyptFemaleHumansInflammationMaleBiomarkersCyclooxygenase 2DinoprostoneInterleukin-4Plasminogen Activator Inhibitor 1PTGS2 protein, humanAlport syndromeCyclooxygenase-2Interleukin 4Plasminogen activating inhibitor 1Prostaglandin E2

Identifiers

PMID39856623
PMCPMC11761226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.